Is Eurofins Scientific profitable in 2025?

Yes. Eurofins reported FY2025 revenue of EUR7,296m (up ~5% YoY), EBITDA of EUR1,561m (up 8%), and EPS growth of 24%, per its Full Year Results Press Release dated January 29, 2026.

Could AI replace Eurofins Scientific's lab testing business?

No. Eurofins' core product is ISO/IEC 17025 accredited physical sample testing with chain-of-custody liability across 950+ labs in 59 countries; AI is used internally for image recognition and anomaly detection but cannot hold accreditation or regulatory sign-off, as of 2026.

Who are Eurofins Scientific's biggest competitors?

SGS, Bureau Veritas, Intertek and TUV SUD are the main peers in the fragmented global testing/inspection/certification market, where the top 7 players hold a small combined share; Labcorp is the closest comparator in clinical diagnostics.

Who owns or controls Eurofins Scientific?

Eurofins is publicly traded on Euronext Paris (part of CAC40 since September 2021) with no parent company, but founder Dr Gilles Martin, Chairman and CEO since 1987, holds a controlling ownership stake as of 2026.

Is Eurofins Scientific growth slowing in 2026?

Yes. After FY2025 organic growth of 4.1%, Q1 2026 organic growth slowed to 2.6% partly due to severe weather and BioPharma softness, prompting AlphaValue/Baader Europe to downgrade the stock to Reduce on July 21, 2026.

Is Eurofins Scientific cutting jobs?

No layoffs are reported; the company states over 65,000 employees across 950+ labs as of its 2025 Annual Report (February 25, 2026), though third-party estimator Revelio Labs separately shows a declining ~59,489 figure for the same period.

Biotech tools companies · France

Eurofins Scientific SE

eurofins.com ↗

Runs 950+ accredited labs worldwide doing food, environmental, and biopharma testing.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Element Materials Technology life sciences deal and E&E divestiture to UL Solutions both expected to close

The call

Growth cooled in early 2026 and analysts flagged it, but the testing work itself still needs accredited labs and regulatory trust that no AI model or single rival currently supplies at this scale.

Eurofins runs thousands of testing laboratories across 60 countries that check products for safety, quality, and regulatory compliance. The business is hard to copy because it requires expensive accreditation from government agencies, years to build trust with regulators like the FDA and EU health authorities, and physical labs that must follow strict chain-of-custody rules that AI cannot replace. The main risk is not competition but the company's governance history and the fact that pharmaceutical companies (a big customer) are spending less right now, which slowed growth in early 2026.

Why

AI pressure: None apparent. AI speeds up image reading and anomaly checks inside the labs but cannot hold the ISO/IEC 17025 accreditation the testing itself requires. Could AI do the core job? Unlikely.

Bigger players: SGS SA and Bureau Veritas. Both compete for the same fragmented testing market and also buy smaller labs, but neither is shown taking customers from Eurofins. Could a giant copy it? No, they are blocked.

What protects it. Accredited labs, chain-of-custody sign-off, and direct ties to regulators like EFSA and the MDR/IVDR bodies that a new entrant or algorithm cannot get overnight.

What would change this call

FY2026 organic growth rate versus company's own full-year target when reported. Shows whether the Q1 2026 slowdown to 2.6% was temporary or a lasting demand shift.
Close of Element Materials Technology North America Life Sciences deal and E&E divestiture to UL Solutions, expected Q4 2026. Confirms Eurofins keeps consolidating rather than losing scale to rivals.
Any formal proceeding opened by a European regulator tied to 2024 Muddy Waters allegations. Would signal governance/trust risk materializing beyond refuted claims.

Key numbers

FY2025 revenue €7,296m, up ~5% (2025-12-31)
FY2025 EBITDA €1,561m, up 8% (2025-12-31)
Q1 2026 organic growth slowed to 2.6% (2026-03-31)

Named risks

Governance and accounting overhang from Muddy Waters 2024 allegations and related-party dealing history. Severity: medium
BioPharma segment cyclicality driving organic growth deceleration to 2.6% in Q1 2026. Severity: medium
Leverage rising toward 2.5x ceiling amid aggressive acquisition pace (39 deals 2025, 10 Q1 2026). Severity: medium
Founder-controlled ownership structure concentrates governance power with Dr Gilles Martin. Severity: low
Pending regulatory approvals for UL Solutions divestiture and Element acquisition, both targeted Q4 2026. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
SGS SA	contesting	Comparable-scale TIC peer; Eurofins is largest single player, ~3% self-claimed share in fragmented market, 2025
Bureau Veritas	contesting	Peer in fragmented global TIC sector, no material share shift reported through 2026
Intertek Group	contesting	Peer TIC player; Eurofins pursuing consolidation via 39 acquisitions in 2025
Labcorp Holdings	contesting	Closest clinical-diagnostics comparator with over 100-country presence, per company materials
Element Materials Technology	gaining on	Eurofins agreed July 20, 2026 to acquire Element's NA Life Sciences Testing unit for $400m

Questions people ask

Is Eurofins Scientific profitable in 2025?: Yes. Eurofins reported FY2025 revenue of EUR7,296m (up ~5% YoY), EBITDA of EUR1,561m (up 8%), and EPS growth of 24%, per its Full Year Results Press Release dated January 29, 2026.
Could AI replace Eurofins Scientific's lab testing business?: No. Eurofins' core product is ISO/IEC 17025 accredited physical sample testing with chain-of-custody liability across 950+ labs in 59 countries; AI is used internally for image recognition and anomaly detection but cannot hold accreditation or regulatory sign-off, as of 2026.
Who are Eurofins Scientific's biggest competitors?: SGS, Bureau Veritas, Intertek and TUV SUD are the main peers in the fragmented global testing/inspection/certification market, where the top 7 players hold a small combined share; Labcorp is the closest comparator in clinical diagnostics.
Who owns or controls Eurofins Scientific?: Eurofins is publicly traded on Euronext Paris (part of CAC40 since September 2021) with no parent company, but founder Dr Gilles Martin, Chairman and CEO since 1987, holds a controlling ownership stake as of 2026.
Is Eurofins Scientific growth slowing in 2026?: Yes. After FY2025 organic growth of 4.1%, Q1 2026 organic growth slowed to 2.6% partly due to severe weather and BioPharma softness, prompting AlphaValue/Baader Europe to downgrade the stock to Reduce on July 21, 2026.
Is Eurofins Scientific cutting jobs?: No layoffs are reported; the company states over 65,000 employees across 950+ labs as of its 2025 Annual Report (February 25, 2026), though third-party estimator Revelio Labs separately shows a declining ~59,489 figure for the same period.

Timeline

2026-07-21AlphaValue/Baader Europe downgraded stock to Reduce
2026-07-20Agreed to acquire Element Materials Technology's NA Life Sciences Testing unit for $400m
2026-05-06Q1 2026 trading update showed organic growth slowed to 2.6%
2026-04-13Agreed to divest Electrical & Electronics testing business to UL Solutions
2026-02-25Published 2025 Annual Report citing 65,000+ employees, 950+ labs
2026-01-29FY2025 results released: revenue EUR7,296m, EBITDA EUR1,561m, stock fell 5.08%
2025-09-02Completed purchase of remaining related-party-owned real estate sites
2025-04-22Reported 6.9% Q1 2025 revenue growth; SYNLAB Spain clinical diagnostics acquisition closed
2024-10-22Independent forensic audit refuted Muddy Waters' 2024 accounting allegations

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Carl Zeiss AG